Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bausch Health Companies Inc (NY: BHC )

8.120 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bausch Health Companies Inc

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Bausch Health Crashes On Unexpected Loss As Bausch & Lomb Starts Trading
The new Bausch & Lomb started trading Tuesday as its former parent company crashed. 
Via Investor's Business Daily
Bausch Health Companies: Q1 Earnings Insights
Bausch Health Companies (NYSE:BHC) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
RBC Capital: What To Expect When Bausch Health Companies Reports Q1 Tomorrow
RBC Capital Markets expects Bausch Health Companies Inc (NYSE: BHC) Q1 FY22 revenue of $2.02 billion (previous $2.04 billion; consensus $2.05 billion) and adjusted EBITDA of $799 million (previous $816... 
Via Benzinga
Earnings Preview: Bausch Health Companies
Bausch Health Companies (NYSE:BHC) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Bausch... 
Via Benzinga
The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru's Pre-EUA Meeting, Conference Presentations And More
Biotech stocks declined yet again in the week ending May 6, dragged lower by macroeconomic concerns following the Federal Reserve's 50-basis-point rate hike. The iShares Biotechnology ETF (NASDAQ:... 
Via Benzinga
Closely Watched Bausch + Lomb IPO Priced Below Expectations
Via Benzinga
Opening Day: Bausch + Lomb Pops In Public Debut
Shares of Bausch + Lomb rose over 11% to end its first trading day at $20. This was the second biggest IPO of the year. Bausch + Lomb opened at $18.50 after having priced its initial public offering at... 
Via Talk Markets
BLCO Stock: 7 Things to Know About the Bausch + Lomb IPO Today
Here's what investors in Bausch + Lomb may want to know about the highly anticipated BLCO stock IPO, which took place today. 
Via InvestorPlace
Morning Brief: Top Financial Stories Dominating on Friday, May 6
Reuters IHG Hotels & Resorts On Way To Recovery As Travel Booms 
Via Benzinga
Why Cramer Recommends Buying Marvell Technology
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Accenture plc (NYSE: ACN) had a great quarter. He recommended buying the stock. 
Via Benzinga
BLCO Stock IPO: When Does Bausch + Lomb Go Public? What Is the Bausch + Lomb IPO Price Range?
Here's what investors may want to know about the upcoming BLCO stock IPO, as Bausch + Lomb is split off from its parent company this week. 
Via InvestorPlace
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks... 
Via Benzinga
Opening Day: Tenon Medical Shares Soar In Market Debut
Shares of Tenon Medical soared in their market debut on Wednesday, opening at $22.05 after the medical-device company had priced its IPO at $5 per share. Meanwhile, Belite Bio opened on April 29 at... 
Via Talk Markets
Jim Cramer Says This Stock Is Still Terrific
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Tredegar Corporation (NYSE: TG) was terrific at the time it became public, and it is terrific now also. 
Via Benzinga
IPO Market Stalls With Potential Blockbuster Deals Waiting For Rebound
Though IPOs in the first quarter plunged to their lowest level in six years, many companies are in the pipeline ready to go public. 
Via Investor's Business Daily
Opening Day: AN2 Therapeutics Rises In Public Debut After Upsized IPO
Shares of AN2 Therapeutics rose over 15% in its trading debut on Friday following an upsized initial public offering. This was only the second initial public offering this month, as the IPO market... 
Via Talk Markets
Opening Day: Cannabis Name Akanda Opens Way Above IPO Pricing, Pulls Back
On its first trading day, Akanda fell about 65% from its opening price of $30, though that opening price was nearly eight-times its IPO price of $4. Meanwhile, startup Knock scrapped its plans to go... 
Via Talk Markets
Opening Day: New Stock Offerings Slump To Lowest Number In A Decade
It was another slow week for IPOs in the U.S. New stock offerings slumped to the lowest number in over a decade last month amid the war in Ukraine and as rising borrowing costs sent share prices... 
Via Talk Markets
Bausch Health Companies Q4 Sales, FY22 Outlook Lag Wall Street View
Bausch Health Companies Inc (NYSE: BHC) has reported Q4 revenues of $2.19 billion, down 1% Y/Y, missing the consensus of $2.80 billion. Excluding the impact of foreign... 
Via Benzinga
Bausch Health Companies: Q4 Earnings Insights
Bausch Health Companies (NYSE:BHC) reported its Q4 earnings results on Wednesday, February 23, 2022 at 07:00 AM. Here's what investors need to know about the... 
Via Benzinga
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase... 
Via Benzinga
Recap: Bausch Health Companies Q4 Earnings
Bausch Health Companies (NYSE:BHC) reported its Q4 earnings results on Wednesday, February 23, 2022 at 07:00 AM. Here's what investors need to know about the... 
Via Benzinga
Preview: Bausch Health Companies's Earnings
Bausch Health Companies (NYSE:BHC) is set to give its latest quarterly earnings report on Wednesday, 2022-02-23. Here's what investors need to know before the announcement.... 
Via Benzinga
Opening Day: Nutraceutical Seller Smart For Life Plunges Following IPO
Shares of Smart for Life plunged about 75% following its initial public offering on the Nasdaq. Blue Water Vaccines opened at $50 after having priced its initial public offering of 2.22 million shares... 
Via Talk Markets
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
Why The Justice Department Is Going After Short Sellers
Federal prosecutors are reportedly ramping up a probe into the activities of short sellers, serving subpoenas and seizing hard drives and mobile phones of prominent "activist... 
Via Benzinga
Two Insider Moonshots Rising on Sudden Buying
Biotech insiders are among the most important investors to pay close attention to. Here are two that show good signs for the future. 
Via InvestorPlace
Jim Cramer Buys The Dip In Salesforce, Marvell And This Health Stock
With the markets falling further into correction territory, Jim Cramer decided to start adding to some of the positions in hi... 
Via Benzinga
Bausch Health's Eye-Care Spin-Off Entity Files For $100M IPO
Bausch & Lomb Corp filed S-1 for its initial public offering, nearly 1.5 years after its parent company, Bausch Health Companies Inc (NYSE: BHC) said it would... 
Via Benzinga
The Daily Biotech Pulse: Bausch Files For Eye Health Unit IPO, LumiraDx Antigen Test Can Detect Omicron, Molecular Partners Discloses Fund Stake
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Corvus Says Chinese Angel Pharma Starts Phase 1/2 Blood Cancer Study Corvus... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.